ENGN
enGene Holdings Inc (ENGN)
Healthcare • NASDAQ • $1.50-12.79%
- Symbol
- ENGN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.50
- Daily Change
- -12.79%
- Market Cap
- $100.48M
- Trailing P/E
- N/A
- Forward P/E
- -0.75
- 52W High
- $12.25
- 52W Low
- $1.45
- Analyst Target
- $21.00
- Dividend Yield
- N/A
- Beta
- -0.01
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Company websiteResearch ENGN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.